Literature DB >> 1765100

Synthesis and evaluation of (+) and (-)-2,2-difluorocitrate as inhibitors of rat-liver ATP-citrate lyase and porcine-heart aconitase.

B A Saxty1, R Novelli, R E Dolle, L I Kruse, D G Reid, P Camilleri, T N Wells.   

Abstract

The enantiomers (+) and (-)-2,2-difluorocitrate have been synthesized. Both are good inhibitors of ATP-citrate lyase, showing competitive inhibition against citrate, with Kis = 0.7 microM for (+)-2,2-difluorocitrate and 3.2 microM for (-)-2,2-difluorocitrate. The inhibition patterns with either ATP or CoA as the varied substrate were uncompetitive and mixed, respectively, but with much weaker inhibition constants. Neither isomer undergoes carbon-carbon bond cleavage as a substrate and there is no evidence of irreversible time-dependent inactivation. When ATP-citrate lyase is incubated with CoA and difluorocitrate, the maximal intrinsic ATPase rate is 10% of the citrate-induced rate for the (+)-enantiomer and 2% for the (-)-enantiomer. 19F-NMR studies confirm that only the (+)-enantiomer is chemically processed. The effects of the difluorocitrate enantiomers on the reaction catalysed by aconitase were examined. (-)-2,2-Difluorocitrate is a competitive inhibitor against citrate (Kis = 1.5 microM), whereas the (+)-enantiomer is a relatively poor mixed inhibitor (Ki greater than 300 microM). The (-)-enantiomer irreversibly inactivates aconitase at 1.1 min-1.mM-1 at 25 degrees C and pH 7.4, whereas no irreversible inhibition is seen with the (+)-enantiomer. Therefore, it would be expected that the (+)-enantiomer would slow the rate of acetyl-CoA synthesis in vivo, without inhibiting the citric acid cycle.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1765100     DOI: 10.1111/j.1432-1033.1991.tb16448.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  3 in total

1.  ATP-citrate lyase deficiency in the mouse.

Authors:  Anne P Beigneux; Cynthia Kosinski; Bryant Gavino; Jay D Horton; William C Skarnes; Stephen G Young
Journal:  J Biol Chem       Date:  2003-12-08       Impact factor: 5.157

Review 2.  Fatty Acids and Breast Cancer: Make Them on Site or Have Them Delivered.

Authors:  William B Kinlaw; Paul W Baures; Leslie E Lupien; Wilson L Davis; Nancy B Kuemmerle
Journal:  J Cell Physiol       Date:  2016-02-16       Impact factor: 6.384

Review 3.  The metabolic advantage of tumor cells.

Authors:  Maurice Israël; Laurent Schwartz
Journal:  Mol Cancer       Date:  2011-06-07       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.